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Abstract
Background: Congenital toxoplasmosis is associated with severe complications. German state health insurance
covers rubella, but not toxoplasmosis, immunity screening. We analysed the effect of socioeconomic factors on the
efficiency of private toxoplasmosis screening during pregnancy.
Methods: Toxoplasmosis and rubella screening data (n = 5402 mothers) were collected within the population-based
Survey of Neonates in Pomerania (SNiP).
Results: At the first-trimester screening, 34.4 % (88.1 %) of expecting mothers were immune to toxoplasmosis (rubella).
Susceptibility for toxoplasmosis (rubella) was observed in 39.6 % (8.9 %) and 25.8 % (2.95 %) were not tested. Data on a
2nd screening were available in a subgroup of women with negative immunity showing less than 45 % participation
rate. Active toxoplasmosis (no rubella) infection was observed in 0.3 % (n = 17) of pregnant women. A multiple logistic
regression model (AIC = 719.67; AUC = 0.725) revealed that the likelihood of participating in a second toxoplasmosis
screening increased among women with a good level of education and a steady partnership and decreased with
paternal unemployment and the absence of breastfeeding. The highest probability of non-participation in toxoplasmosis
screening was found among women with temporal burden and family responsibilities. A cost-benefit analysis showed
that covering general screening for toxoplasmosis with health insurance saved costs.
Conclusion: Toxoplasmosis carried a substantial risk of infection during pregnancy. Although increased socioeconomic
status was positively associated with the participation in toxoplasmosis screening, this was not the case when pregnant
women had strong temporal burden and family responsibilities. This data supports the need for toxoplasmosis screening
among pregnant women as a general healthcare benefit covered by insurance.
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Background
The protozoan Toxoplasma gondii is a major challenge
to public health. The overall rate of toxoplasmosis infec-
tion during pregnancy varies from 1 to 120 per 10,000
births, depending on environmental conditions [1, 2] Al-
though the German Ministry of Health reported eight
cases of acute gestational toxoplasmosis infection in
2009, higher rates seem likely [3].
Following maternal seroconversion, the estimated average
risk of fetal infection during pregnancy is 40–50 %. Fetal risk
correlates inversely with the diaplacental acquisition rate,
which increases from approximately 2 % during the first tri-
mester to 30 % during the second trimester, peaking at ap-
proximately 80 % immediately before delivery [1, 4–6].
During the first two trimesters, acute toxoplasmosis
infection is characterised by septic symptoms, hepatos-
plenomegaly, thrombocytopenia, hyperbilirubinemia,
and central nervous system infections [1, 7, 8] The latter
typically present with encephalitis in combination with
retinochorioiditis, hydrocephalus, intracranial calcifica-
tions, microphthalmia, and microcephaly, as well as cal-
cifying necroses developing from reactive inflammations,
to the point of spontaneous abortion [9]. In contrast, the
majority of fetuses infected during the third trimester
lack pathological findings at birth (70–90 %) [10, 11].
However, in 30–70 % of offspring with clinical abnormal-
ities, those abnormalities are not detected initially; these
children typically have chorioretinitis, hearing loss, and
mental retardation later in life [12, 13]. T. gondii infections
are mostly asymptomatic in adults and immunocompetent
individuals; consequently, acute infections during preg-
nancy usually go unnoticed [8, 14].
Effective prevention strategies are crucial. One possi-
bility is to provide prophylactic therapy to seroconverted
women during pregnancy [15]. When infection is sus-
pected, materno-fetal therapy may be initiated at an
early stage. Depending on the gestational week, standar-
dised therapy regimes of different durations markedly al-
leviate the typical course of toxoplasmosis in neonates
[16, 17]. Knowledge of negative immune status would
also enable women to take appropriate preventive pre-
cautions [18]. In cases of negative immunity, screenings
are conducted at 3-month intervals during gestation to
detect possible infections [16, 19].
In Germany, resident gynaecologists offer toxoplasmosis
screening and the cost of toxoplasmosis screening is borne
by the individual. In contrast, rubella screening is covered
by state health insurance, although an anti-rubella vaccine
is available. The prevalence of rubella vaccination among
German children approaches 75 %, depending on where
they reside. Similar to toxoplasmosis, the transmission rate
of rubella during pregnancy also depends on the time of
maternal infection. Sufficient anti-rubella immunity
excludes congenital rubella syndrome throughout
pregnancy. Women without sufficient immunity are re-
tested later in pregnancy. At the end of pregnancy, a booster
vaccine is recommended for mothers with negative immune
status [20].
The risk of intrauterine toxoplasmosis infection is
higher than that of rubella infection. Less severe disease is
commonly reported in countries in which prenatal screen-
ing and treatment have been systematically implemented
(e.g., France). Gravidic seroconversions (and therefore
cases of congenital toxoplasmosis) were reduced in France
after toxoplasmosis screening was implemented [21].
Regarding efficacy, there is always the question of to
what extent health and monetary concerns can be
weighed against each another. A cost-benefit analysis
intended to assess the efficacy of a screening program
should compare the total cost (the cost of screening and
the cost of treatment in cases of seroconversion) with the
cost of treatment, rehabilitation, and (in the worst cases)
lifelong disability before and after the reduction of cases.
Ideally, the screening cost should be equal to or less than
the cost of moderating congenital toxoplasmosis.
We used population-based data from the Survey of Ne-
onates in Pomerania (SNiP) to analyse the extent to which
toxoplasmosis screening as a privately paid service is used
compared with rubella screening (a standard, insurance-
paid service), and whether toxoplasmosis screening utilisa-
tion correlates with socioeconomic factors.
Methods
Study design
The present study is part of the population-based birth
cohort study “Survey of Neonates in Pomerania (SNiP)”,
conducted from 2002 to 2008. Physicians specially
trained for the study collected data about pregnancy and
births at the participating hospitals. Detailed information
about newborn children and their mothers regarding
neonatal health, morbidity, and mortality was collected
to calculate prevalence rates for major neonatal diseases,
risk factors, and confounding conditions on a cross-
sectional and prospective basis. According to census
data, 7220 babies were born in the study region of Pom-
erania in northeast Germany during the study period. In
SNiP, data from n = 6828 (95 %) babies and their respect-
ive mothers (n = 6747) were assessed, yielding high
population coverage. Exclusions and non-responders
comprised n = 1556 individuals; a minimum dataset was
compiled comprising data on the health status of these
newborns and women, but lacking detailed information
about environmental parameters. From the mothers,
personal data, medical records (149 variables), a personal
interview (84 variables), and a self-administered ques-
tionnaire concerning socioeconomic background (40
variables) were recorded. Details of the SNiP study have
been reported by Ebner et al. [22].
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Population
Data from 5402 mothers of neonates delivered between
May 2002 and June 2008 were analysed for toxoplasmo-
sis and rubella screening, infection, and socioeconomic
background.
Data assessment
All mothers provided written informed consent to partici-
pate in the study, which was approved by the Ethics Com-
mittee of the Ernst Moritz Arndt University, Greifswald.
Data was collected in standardised 5- to 10-min inter-
views. Parents were also asked to complete a question-
naire during their stay on the ward and return it to the
medical staff before discharge. This questionnaire in-
cluded questions about the parents’ social background and
lifestyle. Data about the gestational period and any pre-
ventive examinations was acquired using the mother’s
medical file and maternity card. The collected data was
anonymised and stored in an Access database.
Toxoplasmosis and rubella screening data from 5402
mothers was evaluated. This data contained information
about immunity against toxoplasmosis and rubella (yes/
no/infection during pregnancy/no information available).
Variables were correlated with family status, education
level, gainful employment, and income.
To study toxoplasmosis screening attendance as a pre-
ventive measure, women were classified into two groups ac-
cording to whether or not they underwent toxoplasmosis
screening. Women who underwent toxoplasmosis screen-
ing were stratified into three categories: with positive im-
munity, defined as proof of IgG antibodies in maternal
serum, proof of IgG antibodies in umbilical cord blood, and
no evidence of IgM antibodies in umbilical cord blood
(Category I); with negative immunity, defined as no proof
of IgG antibodies in maternal serum, no proof of IgM anti-
bodies, and no evidence of IgG or IgM antibodies in umbil-
ical cord blood (Category II); and with toxoplasmosis
infection during pregnancy, defined as proof of IgM and
IgG antibodies in maternal blood or proof of IgM and IgG
antibodies in umbilical cord blood (Category III).
For laboratory analysis the Serion Elisa classic Toxo-
plasmosis gondii IgG/IgM tests (Vision/Serion GmbH,
Würzburg, Germany) were used. (Vtox IgG <10UIE) and
(vtox IgM <300 UIE) demonstrate a negative result. Ap-
plying these threshold values result in a sentivity of
98.2 % (97.8 %) and a specificity of 99.4 % (95.7 %) for
IgG (IgM) (information supplied by the manufacturer).
Placental leak occasionally can lead to false-positive IgM
reaction. In these cases, the infants were tested again
several days later, because the half-life of IgM is only ap-
proximately 5 days. A persistent positive or increasing
IgG titer in the infant and/or a positive IgM indicated
congenital infection. Toxoplasmosis PCR in amniotic
fluid was not routinely applied.
In conjunction we use the IgG Avidity Assay. The
method is most useful in woman in the first 16 weeks of
gestation in whom IgM antibodies are found. It also is
useful late in gestation to determine whether infection
was acquired 4 or more months earlier, thereby allowing
for an estimate of the rate of fetal infection at a given
time during gestation [1].
Statistical analysis
All data were stored using a Microsoft Access 2002
(Microsoft Corporation, Redmond, WA, USA) database.
Statistical calculations were performed using SPSS (IBM
SPSS 21.0, IBM Deutschland GmbH, Munich, Germany)
for Windows 7® (Microsoft Corporation) and R (R De-
velopment Core Team, 2011). The mean (SD), median
(range), or numbers of patients were processed for each
baseline characteristic and are depicted separately for so-
cioeconomic factors and screening utilisation. Simple lo-
gistic regression, with screening outcome as a dependent
variable and socioeconomic factors as independent vari-
ables, was used to select variables that were associated
significantly with screening rate. Subsequently, we evalu-
ated these associations (all variables with P < 0.1) in a
multiple logistic regression model (OR 97.5 % CI), taking
into account confounders such as the 40 socioeconomic
variables mentioned in the Study Design subsection.
P-values <0.05 were considered statistically significant.
Health economic evaluation of general screening
We developed a simple decision tree (Additional file 1) to
estimate whether financial coverage of general toxoplas-
mosis screening by health insurance would be beneficial.
We compared the expected value of total direct and indir-
ect costs for two scenarios (represented in the two pri-
mary branches of the decision tree). Scenario 1
represented complete coverage of screening costs by
health insurance, resulting in higher screening participa-
tion and a correspondingly lower number of cases. Sce-
nario 2 represented the status quo in Germany (screening
paid for out-of-pocket). The main input variables of the
model were the costs of screening, treatment, and indirect
costs (loss of lifelong productivity), as well as the likeli-
hoods of screening (subject to scenarios 1 and 2), toxo-
plasmosis, treatment, and death. Data was obtained from
literature [23] and adjusted using findings from SNiP.
Results
Study population
For all pregnant women (n = 5402), utilisation rate for
early rubella screening as a standard service was
97.05 %; the utilisation rate for toxoplasmosis screening
as a private service was 74 % (Fig. 1).
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Screening results: toxoplasmosis vs. rubella immunity
First screening
At the first screening, the rate of anti-toxoplasmosis im-
munity (n = 1856; 34.36 %) was less than one-half the rate of
anti-rubella immunity (n = 4760; 88.11 %). Screening re-
vealed 2140 cases (39.61 %) that lacked toxoplasmosis im-
munity and 481 cases (8.94 %) that lacked rubella immunity.
Data from the mothers’ medical files and maternity cards
provided no information regarding toxoplasmosis immunity
status for 1391 women (25.8 %) and regarding rubella im-
munity status for 159 women (2.95 %). Active toxoplasmosis
infection during pregnancy was observed in 17 women
(0.3 %, CI 95 0.2- 0.6). Infection occurred during pregnancy
at gestational age of up to 10 weeks in n= 6 (35.3 %) cases,
in week 11–18 in n= 6 (35.3 %), in 3 cases there were no in-
formation (Table 1). The mean gestational age of their new-
borns was 40.3 weeks (SD= 1.01). There was suspicious
sonography of the skull in n= 2 (11.76 %) newborns and no
hearing deficit in any of the newborns (neither right or left
ear). Active infection was detected in cord blood from eight
newborns (Table 1).
No active rubella infections were documented.
Second screening
Six hundred fifty-three women who initially screened nega-
tive for toxoplasmosis were offered a second screening
from May 2002 to March 2003; 284 (43.5 % of n = 653)
declined a second screening (Fig. 1). Two hundred eighty-
two women (43.2 %) had a negative screening result; two
(0.31 %) had seroconverted since the first screening, indi-
cating infection during early pregnancy.
Impact of socioeconomic factors on screening
participation: univariate analysis
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Fig. 1 Participation of pregnant women in toxoplasmosis and rubella screening. Data on a 2nd screening were available in a subgroup of
women from 2002–2003
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Correlation of family status with first screening
participation
Participation in the first toxoplasmosis screening corre-
lated significantly with the family status of pregnant
women (n = 3999, p > 0.001). Married pregnant women
living with a spouse had the highest participation rate
(74.5 %); married women separated from a spouse had a
60 % participation rate (Additional file 2: Table S1).
Single pregnant women participated in the first toxo-
plasmosis screening at a much higher rate (75.5 %) than
married pregnant women not living with a spouse
(60.0 %) or divorced pregnant women (59.8 %).
In contrast, we observed no statistically significant cor-
relation between participation in rubella screening and
family status (n = 3999 [62.91 % of the 5402 women in-
cluded in analysis], p = 0.42). Married women and mar-
ried women living separated from a spouse took part in
rubella screening at high rates (97.3 and 91.1 %, respect-
ively). Rubella screening participation was also high
among single (97.9 %), divorced (98.3 %), and widowed
(100 %) women.
Correlation of patient-reported education with first screening
participation
Education level and participation in toxoplasmosis and ru-
bella screenings correlated positively (n = 4813 [89.1 % of
the 5402 women included in analysis], p < 0.001). Mothers
who had 8 years of secondary school and were university-
qualified (Abitur, 83.4 %), had 8 years of secondary school
(Fachhochschulreife, similar to A-levels, 78.50 %), and had
6 years of secondary school (Realschulabschluss, 76 %)
participated more often in toxoplasmosis screening than
mothers who had 5 years of secondary school
(Hauptschulabschluss, 61.1 %), did not earn a school dip-
loma (47.6 %), or were still in school (44.4 %). Participa-
tion in rubella screening was high across all educational
levels (Additional file 3: Table S2).
Correlation between income level and first screening
participation
Expectant mothers’ income level correlated positively
with participation in the first toxoplasmosis screening
(n = 2938 [54.38 % of the 5403 women included in
the analysis], p < 0.001) (Additional file 4: Table S3).
This correlation was not observed for rubella screening.
Influence of socioeconomic factors on participation in the
second toxoplasmosis screening
Attendance at the second toxoplasmosis screening was
higher among women with a higher education level and
Table 1 Treatment and neonatal short-term outcome of 17 Pregnancies with maternal toxoplasma infection. SGA small for gestational
age












Findings in the fetus Treatment
newborn
1 6 + + no + - - no no
2 8 + + no + - - no no
3 8 + + low + + - SGA yes
4 8 + + low + + +a no yes
5 10 + + low ? + - no no






7 11 + + low + + - no no
8 12 + + low inadequate - - SGA no
9 12 + + low + + +a SGA yes
10 14 + + high + +
-a
- no no
11 16 + + low - + + Cerebral Disorders yes
12 17 + + low + + - no no
13 No informatio + + low + + - no no
14 No information + + low No information + - no no
15 No information + + low No information + - no no
16b 20 + + no - + + SGA yes
17b 21 + + no - + + SGA yes
aat repeated blood sampling, bNewborn 16 and 17: detected at the second screening
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women who had been gainfully employed before
pregnancy (Additional file 5: Table S4).
Impact of socioeconomic factors on first screening
participation: multiple logistic regression analysis
We calculated a multiple logistic regression model to
evaluate the associations (all variables with p < 0.1) be-
tween screening participation and each of the studied
socioeconomic factors (family status, education level, in-
come level, steady partnership, gainful employment,
planned pregnancy, and breastfeeding) (OR 97.5 % CI;
Table 2). The model demonstrated a modest fit (AIC =
719.67; AUC = 0.725). When socioeconomic factors were
viewed as cofounders, the likelihood of participating in a
second toxoplasmosis screening increased among
women with a good level of maternal education and a
steady partnership. The likelihood of non-participation
in an adequate toxoplasmosis screening increases by
1.14 with paternal unemployment and by 1.72 in the ab-
sence of breastfeeding.
Table 3 shows the probability of non-participation in
toxoplasmosis screening when socioeconomic variables
were combined in different ways. The highest probability
of non-participation (66 %) was found in pregnant women
with a high educational level, full-employed, planned their
pregnancy, did not intend to breast-feed and lived in a
steady partnership with an unemployed partner.
Health economic evaluation of general screening
Based on the decision tree model (Fig. 1) and the data
provided by [23], we estimated the expected lifelong cost
as $633 USD for full coverage by health insurance and
$1406 USD for out-of-pocket payment. From a societal
perspective, coverage of toxoplasmosis screening by
health insurance is advisable.
Discussion
Substantial pathology in newborns, insufficient screening
strategies, and the lack of a vaccine contribute to T. gondii
as a considerable public health concern. In our cohort,
sufficient immunity was detected in only 34.4 % (n = 1856)
of mothers-to-be; 25.8 % (n = 1391) of women were never
screened, and approximately 40 % (n = 2140) were initially
diagnosed as lacking immunity without sufficient follow-
up. The latter population urgently requires counselling re-
garding preventative measures and re-screening. In con-
trast, 88 % (n = 4760) of pregnant women were effectively
protected against rubella. To avoid potential gestational
toxoplasmosis infection, the immune status of pregnant
women should be monitored at 3-month intervals [8]. But
even worse, less than 45 % of women without immunity
to toxoplasmosis participated in a second screening.
Our prevalence data indicate a gestational infection rate
of 0.3 % (n = 17/5402), and active infection was detected
in cord blood from eight newborns (8/3645; 0.22 %).
These numbers are considerably higher than the re-
cently published report that 8.5 in 10,000 pregnant
women have toxoplasmosis, and 1.0 per 10 000 infants
had congenital toxoplasmosis (13 % mean transmission
rate) in Austria [24]. While in Austria toxoplasmosis
screening in pregnancy is covered by national health-
care providers, this is not the case in Germany. The
Law on the Prevention of infection provides anonym-
ous mandatory reporting to the Robert-Koch-Institute
(German Ministry of Health). But only 11 cases of
active congenital toxoplasmosis were reported in 2008,
[3] modelled calculations based on our study data
yielded much higher rates, in agreement with other
published calculations [8]. Furthermore, congenital
toxoplasmosis often goes unreported; cases may not be
detected until patients experience manifestations as
adults [25].
A retrospective analysis at the Ludwig-Maximillian-
University in Munich (LMU) reported on toxoplasmosis
screening in 15,856 pregnancies between 2001 and 2008
[26, 27]. Toxoplasmosis serology was completed in
39.99 %; of these, 62.47 % were seronegative and 13.02 %
were seropositive. Seroconversion was discovered in
0.14 % of these women, resulting in a calculated inci-
dence of <0.057 %. This difference in immunity level
may be explained by geography: LMU patient population
is urban, while participants in the SNiP study live in
Table 2 Impact of socioeconomic factors on first screening participation: multiple logistic regression analysis with non-participation
in toxoplasmosis screening as the dependent variable
OR CI 2.50 % 97.5 % Sign test p-value p
Solid partnership (=yes) 0.39 0.18 0.78 0.0115*
Maternal education level (=high) 0.68 0.57 0.80 0.000***
Job situation, mother (=employed) 1.14 1.03 1.25 0.0095**
Job situation, father (=employed) 0.86 0.69 1.14 0.0487*
Planned pregnancy 1.4 1.10 1.79 0.0071**
Absence of breastfeeding 1.7 1.35 2.18 0.000***
an = 3399 women (62.91 % of the 5402 included in the analysis)
***p < 0.001; **p < 0.01; *p < 0.05
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Mecklenburg-Western Pomerania. In the latter state,
which is dominated by farming communities, women
are exposed to a greater environmental risk of contract-
ing toxoplasmosis (seropositive: SNiP 34.36 % vs. LMU
13.02 %; seronegative: SNiP 39.61 % vs. LMU 62.47 %).
Each screening is subject to a fee that is paid by the in-
dividual [25]. Therefor, the current screening strategy
(screening as a private service) may be one reason for
the insufficient number of toxoplasmosis screenings. Al-
though one screening during pregnancy is sufficient for
women with positive immune status, cases that lack im-
munity require three examinations to identify gestational
infections in adequate time to initiate materno-fetal
therapy [25]. We contrast this situation against rubella
screening, a standard service covered by state health in-
surance. The rate of maternal participation is 23 %
higher for rubella screening than for toxoplasmosis
screening, although vaccination renders the rate of ru-
bella immunity (88.11 %) much higher than that of toxo-
plasmosis immunity (34.36 %).
Socioeconomic factors also have a marked negative in-
fluence on the rate of screening participation. We have
demonstrated that attendance at toxoplasmosis screen-
ings is higher among mothers with higher education
levels and gainful employment preceding pregnancy.
In this study, lower socioeconomic status was a clear
risk factor for non-participation in toxoplasmosis screen-
ing. Toxoplasmosis is more likely to occur among neo-
nates born to mothers in the lower social strata. Although
increased socioeconomic status was positively associated
with the participation in toxoplasmosis screening, this was
not the case when pregnant women had strong temporal
burden and family responsibilities. Our model demon-
strated that mothers who are in a long-term relationship,
have graduated from school, are working full-time, with a
partner who is not working full-time (student, in training),
undergoing an intended/planned pregnancy, and with no
intention of breastfeeding are least likely to make use of
toxoplasmosis screening programs (Table 3). These effects
may not be observed as strongly in rubella screenings as
the costs for this are covered by public insurance, whereas
toxoplasmosis screenings are not and thus also require
additional consulting with the responsible physicians. This
is associated with more time having to be contributed by
the mother, which may have aggravated the negative effect
on participation rate in toxoplasmosis screening.
Our analysis shows that the expected lifelong cost for
out-of-pocket payment are 2.2 fold the cost for full
coverage by health insurance, i.e., the society could save
773 USD per pregnancy if the health insurance had the
obligation to pay for screening for toxoplasmosis. This
analysis is preliminary as some potential arms of the de-
cision tree (Fig. 1) are not included, such as false positive
sero-conversions with unnecessary amniocentesis and
fetal loss. However, with a ratio of 2.2 the results are
quite robust and allow the general statement that
screening is cost-effective. This finding is in line with
prior findings that general toxoplasmosis screening is
highly cost-efficient from a societal perspective [23], but
more research on the economics of toxoplasmosis
screening is needed to address the complete complexity
of the epidemiological, economic and social situation.
Stillwaggon et al. [23] we highlight a general dilemma
of healthcare financing: cost-effectiveness of general
screening from a societal perspective does not ensure
implementation by health insurance. The high figures
provided by Stillwaggon et al [23] include indirect costs
(i.e., lifelong loss of productivity, fatalities), which are ir-
relevant from the perspective of health insurance. The
asymmetry of societal and institutional benefits regularly
requires legal action (e.g., the obligatory financing of
toxoplasmosis screening by health insurance). Our find-
ings also warrant additional research regarding the
health economics of so-called neglected diseases (Fig. 1).
Because the risk of toxoplasmosis infection is higher
in mothers-to-be with negative immune status, they
should be screened three times during pregnancy to de-
tect potential seroconversion as early as possible. In our
study we found 15 cases of toxoplasmosis out of 4011
woman at the first screening, which means that 267











Breastfeeding Probability of non-
participation
Yesa Yesb Full Time No education Yes No 66.01 %
Yes Yes Full Time No education Yes No 62.92 %
Yes Yes Unemployed At school Yes No 61.97 %
Yes Yes Unemployed At school Yes No 58.95 %
Yes Yes Unemployed No education Yes Yes 55.42 %
Yes Yes Full Time At school No No 54.76 %
Yes Yes Full Time At school No No 54.76 %
an = 4813 women (89.1 % of the 5402 included in the analysis)
bmother in a stable partnership
cmother has completed a professional education
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mothers were screened to detect one case of toxoplas-
mosis. Furthermore, the rate of mothers with maternal
toxoplasmosis who were treated to prevent one treat-
ment in the offspring was 9/3 (Table 1) [28]. In France,
this screening strategy reduced congenital toxoplasmosis
cases by 10-fold [21]. Furthermore, the Austrian toxo-
plasmosis register reported recently that early detection
of toxoplasmosis in pregnancy allowed adequate treat-
ment with a 6.fold reduction in transmission rate [24].
In our cohort, participation has to be regarded as inad-
equate during toxoplasmosis screenings at all stages.
A limitation of our study is the lack of serologic follow
up data of newborns at risk during the first year of life.
A second limitation is that data on the acceptance of a
2nd screening derived only from a subgroup of our co-
hort. These limitations may have resulted in a higher in-
cidence of both toxoplasmosis infections in pregnancy
and in the newborn in our population.
In conclusion, private toxoplasmosis screening in preg-
nancy carries a substantial risk of undiagnosed infection.
Participation in toxoplasmosis screening was influenced by
socioeconomic factors. Increased socioeconomic status was
positively associated with the participation in toxoplasmosis
screening. But this was not the case when pregnant women
had strong temporal burden and family responsibilities. It
seems reasonable to make toxoplasmosis screening a stand-
ard of care and a reimbursable healthcare benefit for all
pregnant women, as our data show that large numbers of
pregnant women do not participate adequately in this
screening. These considerations reflect the urgent need for a
globally applicable and consistent toxoplasmosis screening
strategy for pregnant women. Such a strategy could improve
awareness, knowledge, and prevention, and could guarantee
early treatment in cases of gestational infection. Taking into
account the potential follow-up costs for neonates with un-
diagnosed toxoplasmosis infections, health economic con-
siderations may also support the general screening of all
women while trying to conceive and/or during early
pregnancy.
Conclusion
Toxoplasmosis carried a substantial risk of infection
during pregnancy. Although increased socioeconomic
status was positively associated with the participation in
toxoplasmosis screening, this was not the case when
pregnant women had strong temporal burden and family
responsibilities. This data supports the need for toxo-
plasmosis screening among pregnant women as a gen-
eral healthcare benefit covered by insurance.
Taking into account the potential follow-up costs for neo-
nates with undiagnosed toxoplasmosis infections, health
economic considerations may also support the general
screening of all women while trying to conceive and/or dur-
ing early pregnancy.
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